Breast Cancer Clinical Trials

Showing 1521-1540 of 5,597 trials

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

NCT05463601

Neutropenia is a common complication from dalpiciclib. Mecapegfilgramtim (code name HHPG-19K), a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF), has been developed. The study aim to evaluate the safety and efficiency of mecapegfilgrastim for prophylaxis of dalpiciclib -induced neutropenia in patients with advanced HR+/HER2- breast cancer.

Metastatic Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University132 participantsStarted Aug 2022

Guangzhou, Guangdong, China

COMPLETEDNA

Hypofractionated PBI After BCS for Low-risk Breast Cancer Patients

NCT03411174

The study was designed to evaluate the feasibility and safety of hypofractionated partial breast irradiation after breast-conserving surgery for low-risk breast cancer patients.

Breast Cancer

Fudan University220 participantsStarted Apr 2015

Shanghai, Shanghai Municipality, China

RECRUITINGPhase 2

Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)

NCT06964906

The purpose of this study is to evaluate the efficacy and safety of high-intensity focused ultrasound (HIFU) combined with toripalimab plus chemotherapy versus chemotherapy as neoadjuvant therapy for ER+/HER2- breast cancer.

ER+/HER2- Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University140 participantsStarted Mar 2025

Hangzhou, Zhejiang, China

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Hypofractionated PBI After BCS for Low-risk Breast Cancer Patients

Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)

Related Searches

A Real World Study of Sacituzumab Govitecan

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma

PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women

The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

Investigation of the Effect of Erector Spinae Plane Block on Systemic Immuno-Inflammatory Index

Tempus Priority Study: A Pan-tumor Observational Study

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer

A Study of Effect of Megakaryocytes and Platelets in Breast Cancer

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer

Heart Health After Cancer Treatment (HEART-ACT)

Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC